Abstract
OBJECTIVES: Recombinant erythropoietin (rEpo) has been administered to women with postpartum anemia in an attempt to accelerate their increase in hemoglobin concentration and reduce postpartum transfusions. However, it is not clear whether such an approach can be supported by evidence and should be generally recommended.
STUDY DESIGN AND METHODS: Medical and scientific literature from January 1990 to December 2002 was searched and studies that reported the administration of rEpo to women with postpartum anemia were evaluated.
RESULTS: Eight evaluated studies reported an aggregate of 480 women; 300 rEpo recipients and 180 controls. Significant diversity in design was observed in rEpo dose, route of rEpo administration, iron supplementation, and baseline hemoglobin. No significant safety concerns were reported. In all five studies where it was reported, 4 to 7 days after beginning treatment, greater increases in hemoglobin concentration were observed among the rEpo recipients than among the controls. However, heterogeneity of results (Q-test statistic, p<0.01) indicated that it was not appropriate to apply summary statistics. The effect of rEpo on postpartum transfusion rate was not measurable by summary statistics because of the limited number of transfusions given (no transfusions among the 300 rEpo recipients vs two transfusions among the 180 controls).
CONCLUSION: Administration of rEpo to women with postpartum anemia appears to be safe, and is associated with a trend toward a faster increase in hemoglobin concentration. However, its efficacy in terms of diminishing postpartum transfusions is unproven.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Milasinovic L, Kapamadzija A, Dobric L, Petrovic D . Postpartum anemia—incidence and etiology. Med Pregl 2000;53:394–399.
Huch R, Huch A . Erythropoietin in obstetrics. Hematol Oncol Clin North Am 1994;1028:1021–1040.
Atkinson LA, Baxley EG . Postpartum fatigue. Am Fam Phys 1994;50:113–118.
Mara M, Zivny J, Eretova V, et al. Changes in markers of anemia and iron metabolism and how they are influenced by antianemics in postpartum period. Acta Obstet Gynecol Scand 2001;80:142–148.
Vora M, Gruslin A . Erythropoietin in obstetrics. Obstet Gynecol Surv 1998;53:500–508.
Mulrow C, Oxman AD, editors. Cochrane. Collaborative Handbook (updated 21 Oct 1996). Available in the Cochrane Library (database on disk and CD-ROM). The Cochrane Collaboration; issue 3. Oxford Updated software; Updated quarterly. Available from: BMJ Publishing Group, London 1996.
Petitti D . Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York/Oxford: Oxford University Press; 2000.
Arthur W, Bennett W, Huffcut A . Conducting Meta-Analysis Using SAS: Multivariate Applications. Mahwah, NJ: Lawrence Eribaum Associates, Inc.; 2001.
Zimmermann R, Breymann C, Richter C, Huch R, Huch A . rhEPO treatment of postpartum anemia. J Perinat Med 1995;23:111–117.
Lebrecht A . Anemia in puerperium; parenteral iron substitution renders erythropoietin therapy dispensable. Geburtshilfe Frauenheilkd 1995;55:167–170.
Malinova M . Human recombinant erythropoietin in the treatment of the severe anemia following labor (a preliminary report). Akush Ginekol (Soffia) 1999;38:13–15.
Danko J, Svirohva V, Visnovsky V . Treatment of postpartum anaemia using recombination human erythropoietin. Gynekolog (Czech Rep) 1992;1:4–7.
Danko J, Huch R, Huch A . Epoietin alfa for treatment of postpartum anaemia. Lancet 1990;335:737–738.
Huch A, Eichhorn KH, Danko J, Lauener PA, Huch R . Recombinant human erythrtopoietin in the treatment of postpartum anemia. Obstet Gynecol 1992;80:127–131.
Zimmermann R, Breymann C, Huch R, Huch A . rHuEPO in the treatment of postpartum anemia: subcutaneous versus intravenous administration. Clin Invest 1994;72:S25–S30.
Meyer J, Eichhorn KH, Vetter K, et al. Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well? J Perinat Med 1995;23:99–109.
Breymann C, Zimmermann R, Huch A, Huch R . Use of recombinant human erythropoietin in combination with parenteral iron in the treatment of postpartum anaemia. Eur J Clin Invest 1996;26:123–130.
Makrydimas G, Lolis D, Lialios G, Tsiara S, Georgiou I, Bourantas K . Recombinant human erythropoietin treatment of postpartum anemia, preliminary results. Eur J Obstet Gynecol Reprod Biol 1998;81:27–31.
Breymann C, Richter C, Huttner R, Huch R, Huch A . Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only. in patients with postpartum anaemia and blunted erythropoiesis. Eur J Clin Invest 2000;30:154–161.
Goodnough LT, Skikne B, Brugnara C . Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823–833.
Richardson D . Clinical factors influencing sensitivity and response to epoietin. Nephrol Dial Transplant 2002;17(S1):53–59.
Breymann C . Iron deficiency and anaemia in pregnancy: modern aspects of diagnosis and therapy. Blood Cells Mol Dis 2002;29:506–516.
Bayoumeu F, Subiran-Buisset C, Baka N, Legagneur H, Monnier-Barbarino P, Laxenaire MC . Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002;186:662–667.
Beguin Y, Lipscel G, Oris R, Thoumsin H, Fillet G . Serum immunoreactive erythropoietin during pregnancy and in the early postpartum. Br J Haematol 1990;76:545–549.
Goldstein J, Garry D, Maulik D . Obstetric conditions and erythropoietin levels. Am J Obstet Gynecol 2000;182:1055–1057.
Kashiwagi M, Breymann C, Huch R, Huch A . Hypertension in a pregnancy with renal anemia after recombinant human erythropoietin (rhEPO) therapy. Arch Gynecol Obstet 2002;267:54–56.
Brown MS, Keith JF . Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: a randomized trial. Pediatrics 1999;104:210–215.
Egrie JC, Browne JK . Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(Suppl 3):3–13.
Smith RE, Jaiyesimi IA, Meza LA, et al.Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001;84(Suppl 1):24–30.
MacDougall IC . An overview of the efficacy and safety of novel erythropoiesis timulating protein (NESP). Nephrol Dial Transplant 2001;16(Suppl 3):14–21.
Nissenson AR . Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 2001;38:1390–1397.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kotto-Kome, A., Calhoun, D., Montenegro, R. et al. Effect of Administering Recombinant Erythropoietin to Women with Postpartum Anemia: A Meta-analysis. J Perinatol 24, 11–15 (2004). https://doi.org/10.1038/sj.jp.7211017
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7211017
This article is cited by
-
Gaps in the evidence for prevention and treatment of maternal anaemia: a review of systematic reviews
BMC Pregnancy and Childbirth (2012)
-
Postpartum anemia II: prevention and treatment
Annals of Hematology (2012)